1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Flutiform (Asthma) - Forecast and Market Analysis to 2023

Flutiform (Asthma) - Forecast and Market Analysis to 2023

  • August 2014
  • -
  • GlobalData
  • -
  • 53 pages

Summary

Table of Contents

Flutiform (Asthma) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Flutiform (Asthma) - Forecast and Market Analysis to 2023”. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

SkyePharma’s Flutiform is an FDC of fluticasone propionate and formoterol fumarate. Fluticasone propionate is a synthetic corticosteroid with strong anti-inflammatory activity. Fluticasone can bind to glucocorticoid receptors with high affinity and inhibit the secretion of mediators involved in asthma, such as histamine, eicosanoids, leukotrienes, and cytokines. It is three times more potent than budesonide and two times more potent than the active metabolite of beclomethasone dipropionate. Formoterol fumarate is a LABA that exerts its bronchodilatory activity locally in the lung. LABAs act by stimulating intracellular adenylate cyclase, resulting in increased cAMP levels, which, in turn, cause relaxation of bronchial smooth muscle, inhibiting the release of hypersensitivity mediators, such as histamine and leukotrienes, from cells, especially mast cells.

Scope

- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Flutiform including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Flutiform for the top seven countries from 2013 to 2023.
- Sales information covered for France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Asthma
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Flutiform performance
- Obtain sales forecast for Flutiform from 2013-2023 in top seven countries (France, Germany, Italy, Spain, the UK, Japan and Australia)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025 Summary Hyperparathyroidism (HPT) is a common endocrinal disorder characterized by excessive plasma levels of parathyroid ...

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025 Summary Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections ...


Download Unlimited Documents from Trusted Public Sources

Insulin Market and Diabetes Statistics in the US

  • March 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Diabetes Statistics

  • March 2017
    10 pages
  • Diabetes  

    Therapy  

View report >

Therapy Market and Cancer Immunotherapy Market - Forecast

  • March 2017
    2 pages
  • Therapy  

    Cancer Immunoth...  

    Monoclonal Anti...  

  • United States  

    United Kingdom  

    Europe  

View report >

Related Market Segments :

Therapy
Asthma

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.